Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 358.17 Billion KRW | 4.19% |
| 2022 | 343.75 Billion KRW | -7.04% |
| 2021 | 369.78 Billion KRW | -0.97% |
| 2020 | 373.39 Billion KRW | 3.48% |
| 2019 | 360.83 Billion KRW | 12.23% |
| 2018 | 321.51 Billion KRW | 9.38% |
| 2017 | 293.94 Billion KRW | -7.75% |
| 2016 | 318.63 Billion KRW | 80.1% |
| 2015 | 176.91 Billion KRW | 119.19% |
| 2014 | 80.71 Billion KRW | 425.59% |
| 2013 | -24.79 Billion KRW | 48.03% |
| 2012 | -47.7 Billion KRW | -103.58% |
| 2011 | -23.43 Billion KRW | -285.84% |
| 2010 | 12.6 Billion KRW | -74.38% |
| 2009 | 49.21 Billion KRW | -37.45% |
| 2008 | 78.68 Billion KRW | 6521.68% |
| 2007 | 1.18 Billion KRW | 106.05% |
| 2006 | -19.63 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 399.56 Billion KRW | 11.55% |
| 2024 Q2 | 464.29 Billion KRW | 16.2% |
| 2023 Q4 | 358.17 Billion KRW | 33.1% |
| 2023 FY | 358.17 Billion KRW | 4.19% |
| 2023 Q2 | 300.32 Billion KRW | -0.22% |
| 2023 Q1 | 300.99 Billion KRW | -12.44% |
| 2023 Q3 | 269.1 Billion KRW | -10.4% |
| 2022 FY | 343.75 Billion KRW | -7.04% |
| 2022 Q3 | 315.93 Billion KRW | -2.68% |
| 2022 Q4 | 343.75 Billion KRW | 8.81% |
| 2022 Q2 | 324.62 Billion KRW | 5.26% |
| 2022 Q1 | 308.4 Billion KRW | -16.6% |
| 2021 Q2 | 383.3 Billion KRW | 10.4% |
| 2021 FY | 369.78 Billion KRW | -0.97% |
| 2021 Q1 | 347.2 Billion KRW | -7.01% |
| 2021 Q3 | 359.86 Billion KRW | -6.12% |
| 2021 Q4 | 369.78 Billion KRW | 2.76% |
| 2020 Q2 | 317.57 Billion KRW | 0.93% |
| 2020 Q1 | 314.65 Billion KRW | -12.8% |
| 2020 FY | 373.39 Billion KRW | 3.48% |
| 2020 Q3 | 375.66 Billion KRW | 18.29% |
| 2020 Q4 | 373.39 Billion KRW | -0.61% |
| 2019 Q2 | 346.79 Billion KRW | 6.79% |
| 2019 FY | 360.83 Billion KRW | 12.23% |
| 2019 Q1 | 324.73 Billion KRW | 1.0% |
| 2019 Q4 | 360.83 Billion KRW | 9.6% |
| 2019 Q3 | 329.24 Billion KRW | -5.06% |
| 2018 Q3 | 367.3 Billion KRW | 6.06% |
| 2018 Q1 | 319.8 Billion KRW | 8.8% |
| 2018 FY | 321.51 Billion KRW | 9.38% |
| 2018 Q4 | 321.51 Billion KRW | -12.47% |
| 2018 Q2 | 346.3 Billion KRW | 8.29% |
| 2017 Q4 | 293.94 Billion KRW | -7.9% |
| 2017 FY | 293.94 Billion KRW | -7.75% |
| 2017 Q3 | 319.16 Billion KRW | 5.11% |
| 2017 Q2 | 303.64 Billion KRW | -9.71% |
| 2017 Q1 | 336.31 Billion KRW | 5.55% |
| 2016 Q4 | 318.63 Billion KRW | 22.25% |
| 2016 Q1 | 159.81 Billion KRW | -9.67% |
| 2016 Q2 | 258.98 Billion KRW | 62.06% |
| 2016 FY | 318.63 Billion KRW | 80.1% |
| 2016 Q3 | 260.63 Billion KRW | 0.64% |
| 2015 FY | 176.91 Billion KRW | 119.19% |
| 2015 Q2 | 53.1 Billion KRW | -6.75% |
| 2015 Q3 | 124.72 Billion KRW | 134.84% |
| 2015 Q1 | 56.95 Billion KRW | -29.44% |
| 2015 Q4 | 176.91 Billion KRW | 41.85% |
| 2014 Q2 | -37.33 Billion KRW | -5.49% |
| 2014 Q3 | -28.75 Billion KRW | 22.98% |
| 2014 FY | 80.71 Billion KRW | 425.59% |
| 2014 Q4 | 80.71 Billion KRW | 380.68% |
| 2014 Q1 | -35.39 Billion KRW | -42.77% |
| 2013 FY | -24.79 Billion KRW | 48.03% |
| 2013 Q3 | -65.88 Billion KRW | -3.41% |
| 2013 Q2 | -63.71 Billion KRW | 5.08% |
| 2013 Q4 | -24.79 Billion KRW | 62.37% |
| 2013 Q1 | -67.12 Billion KRW | -40.73% |
| 2012 Q1 | -24.5 Billion KRW | 0.0% |
| 2012 Q4 | -47.7 Billion KRW | 0.0% |
| 2012 FY | -47.7 Billion KRW | -103.58% |
| 2011 Q1 | -6.66 Billion KRW | 0.0% |
| 2011 FY | -23.43 Billion KRW | -285.84% |
| 2011 Q3 | -7.19 Billion KRW | 3.96% |
| 2011 Q2 | -7.49 Billion KRW | -12.52% |
| 2010 Q1 | 49.21 Billion KRW | -25.93% |
| 2010 FY | 12.6 Billion KRW | -74.38% |
| 2010 Q2 | -526 Thousand KRW | -100.0% |
| 2010 Q3 | 12.1 Billion KRW | 2300889.35% |
| 2009 Q2 | 47.63 Billion KRW | 0.0% |
| 2009 Q4 | 66.44 Billion KRW | 78.69% |
| 2009 Q3 | 37.18 Billion KRW | -21.94% |
| 2009 FY | 49.21 Billion KRW | -37.45% |
| 2008 Q3 | 46.78 Billion KRW | 163.31% |
| 2008 Q2 | 17.76 Billion KRW | 0.0% |
| 2008 Q4 | 55.71 Billion KRW | 19.07% |
| 2008 FY | 78.68 Billion KRW | 6521.68% |
| 2007 FY | 1.18 Billion KRW | 106.05% |
| 2007 Q2 | -13.27 Billion KRW | 0.0% |
| 2007 Q4 | -4.32 Billion KRW | 37.69% |
| 2007 Q3 | -6.93 Billion KRW | 47.72% |
| 2006 FY | -19.63 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3969.168% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 37.384% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | -15.217% |
| HANDOK Inc. | 283.45 Billion KRW | -26.362% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -1684.452% |
| Yuhan Corporation | -69.18 Billion KRW | 617.7% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -84.675% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 9817.756% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 30.838% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 1204.401% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -373.313% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -872.324% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -334.049% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -1326.528% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3969.168% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 324.075% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | -78.246% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -109.53% |
| JW Holdings Corporation | 480.68 Billion KRW | 25.486% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -117.628% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -304651.176% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -132.024% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -15133.088% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -1457.2% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -104.705% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -589.141% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -3969.168% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -126.27% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -132.024% |
| Yuhan Corporation | -69.18 Billion KRW | 617.7% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -163.383% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -500.223% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 16.537% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -132.024% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -208.146% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -2080.677% |
| CKD Bio Corp. | 143.29 Billion KRW | -149.957% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -208.596% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 1588.583% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 900.683% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -15133.088% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 15.292% |
| Boryung Corporation | 187.72 Billion KRW | -90.797% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 598.577% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -373.313% |
| JW Lifescience Corporation | 26.09 Billion KRW | -1272.821% |